Is MYGN or SVRA more profitable?

Savara has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Savara's return on equity. Company Net Margins Return on Equity Return on Assets Myriad Genetics -13.96% -16.09% -8.10% Savara N/A -90.28% -68.95%

Does the media prefer MYGN or SVRA?

In the previous week, Myriad Genetics and Myriad Genetics both had 1 articles in the media. Myriad Genetics' average media sentiment score of 0.30 beat Savara's score of -0.60 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Savara 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media refer more to FBRX or MYGN?

In the previous week, Forte Biosciences had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 3 mentions for Forte Biosciences and 1 mentions for Myriad Genetics. Forte Biosciences' average media sentiment score of 0.38 beat Myriad Genetics' score of 0.30 indicating that Forte Biosciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Forte Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor MYGN or WVE?

In the previous week, WAVE Life Sciences had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 2 mentions for WAVE Life Sciences and 1 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.30 beat WAVE Life Sciences' score of -0.97 indicating that Myriad Genetics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral WAVE Life Sciences 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Negative

Does the media refer more to SANA or MYGN?

In the previous week, Sana Biotechnology had 5 more articles in the media than Myriad Genetics. MarketBeat recorded 6 mentions for Sana Biotechnology and 1 mentions for Myriad Genetics. Sana Biotechnology's average media sentiment score of 0.56 beat Myriad Genetics' score of 0.30 indicating that Sana Biotechnology is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sana Biotechnology 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Myriad Genetics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Myriad Genetics (MYGN) Competitors

$3.20 -0.02 (-0.62%)

As of 08/21/2026 04:00 PM Eastern

Compare

MYGN vs. SVRA, FBRX, WVE, SANA, and AVTX

Should you buy Myriad Genetics stock or one of its competitors? Myriad Genetics's main competitors and comparable companies include Savara (SVRA), Forte Biosciences (FBRX), WAVE Life Sciences (WVE), Sana Biotechnology (SANA), and Avalo Therapeutics (AVTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Myriad Genetics compare to Savara?

Myriad Genetics (NASDAQ:MYGN) and Savara (NASDAQ:SVRA) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Savara has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Savara's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
Savara	N/A	-90.28%	-68.95%

Myriad Genetics presently has a consensus price target of $4.90, indicating a potential upside of 53.13%. Savara has a consensus price target of $10.14, indicating a potential upside of 81.45%. Given Savara's stronger consensus rating and higher probable upside, analysts clearly believe Savara is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
Savara	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

Myriad Genetics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, Savara has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market.

In the previous week, Myriad Genetics and Myriad Genetics both had 1 articles in the media. Myriad Genetics' average media sentiment score of 0.30 beat Savara's score of -0.60 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Savara	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 87.9% of Savara shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by insiders. Comparatively, 5.3% of Savara shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Savara has lower revenue, but higher earnings than Myriad Genetics. Savara is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.37	-$365.90M	-$1.19	N/A
Savara	N/A	N/A	-$118.84M	-$0.58	N/A

Summary

Savara beats Myriad Genetics on 8 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to Forte Biosciences?

Forte Biosciences (NASDAQ:FBRX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their analyst recommendations, media sentiment, earnings, institutional ownership, valuation, profitability, risk and dividends.

Forte Biosciences presently has a consensus price target of $71.67, indicating a potential downside of 6.83%. Myriad Genetics has a consensus price target of $4.90, indicating a potential upside of 53.13%. Given Myriad Genetics' higher probable upside, analysts clearly believe Myriad Genetics is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Forte Biosciences	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Myriad Genetics	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

Forte Biosciences has higher earnings, but lower revenue than Myriad Genetics. Forte Biosciences is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Forte Biosciences	N/A	N/A	-$69.38M	-$4.65	N/A
Myriad Genetics	$824.50M	0.37	-$365.90M	-$1.19	N/A

Forte Biosciences has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Forte Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Forte Biosciences	N/A	-94.82%	-77.68%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Forte Biosciences has a beta of 2.6, indicating that its stock price is 160% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.69, indicating that its stock price is 69% more volatile than the broader market.

77.6% of Forte Biosciences shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 4.4% of Forte Biosciences shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Forte Biosciences had 2 more articles in the media than Myriad Genetics. MarketBeat recorded 3 mentions for Forte Biosciences and 1 mentions for Myriad Genetics. Forte Biosciences' average media sentiment score of 0.38 beat Myriad Genetics' score of 0.30 indicating that Forte Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Forte Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Myriad Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Forte Biosciences and Myriad Genetics tied by winning 7 of the 14 factors compared between the two stocks.

How does Myriad Genetics compare to WAVE Life Sciences?

Myriad Genetics (NASDAQ:MYGN) and WAVE Life Sciences (NASDAQ:WVE) are both small-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, valuation, profitability, dividends and risk.

Myriad Genetics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market. Comparatively, WAVE Life Sciences has a beta of -1.26, suggesting that its share price is 226% less volatile than the broader market.

99.0% of Myriad Genetics shares are held by institutional investors. Comparatively, 89.7% of WAVE Life Sciences shares are held by institutional investors. 1.9% of Myriad Genetics shares are held by company insiders. Comparatively, 24.3% of WAVE Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Myriad Genetics has a net margin of -13.96% compared to WAVE Life Sciences' net margin of -309.73%. Myriad Genetics' return on equity of -16.09% beat WAVE Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Myriad Genetics	-13.96%	-16.09%	-8.10%
WAVE Life Sciences	-309.73%	-50.36%	-40.06%

In the previous week, WAVE Life Sciences had 1 more articles in the media than Myriad Genetics. MarketBeat recorded 2 mentions for WAVE Life Sciences and 1 mentions for Myriad Genetics. Myriad Genetics' average media sentiment score of 0.30 beat WAVE Life Sciences' score of -0.97 indicating that Myriad Genetics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Myriad Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
WAVE Life Sciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Negative

Myriad Genetics currently has a consensus target price of $4.90, indicating a potential upside of 53.13%. WAVE Life Sciences has a consensus target price of $22.53, indicating a potential upside of 325.89%. Given WAVE Life Sciences' stronger consensus rating and higher probable upside, analysts plainly believe WAVE Life Sciences is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Myriad Genetics	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86
WAVE Life Sciences	1 Sell rating(s)	1 Hold rating(s)	14 Buy rating(s)	0 Strong Buy rating(s)	2.81

WAVE Life Sciences has lower revenue, but higher earnings than Myriad Genetics. WAVE Life Sciences is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Myriad Genetics	$824.50M	0.37	-$365.90M	-$1.19	N/A
WAVE Life Sciences	$42.73M	24.39	-$204.38M	-$1.09	N/A

Summary

Myriad Genetics and WAVE Life Sciences tied by winning 8 of the 16 factors compared between the two stocks.

How does Myriad Genetics compare to Sana Biotechnology?

Sana Biotechnology (NASDAQ:SANA) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, media sentiment, valuation, profitability, analyst recommendations, earnings and dividends.

88.2% of Sana Biotechnology shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 25.4% of Sana Biotechnology shares are owned by company insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Sana Biotechnology presently has a consensus price target of $9.33, suggesting a potential upside of 138.70%. Myriad Genetics has a consensus price target of $4.90, suggesting a potential upside of 53.13%. Given Sana Biotechnology's stronger consensus rating and higher possible upside, equities analysts plainly believe Sana Biotechnology is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sana Biotechnology	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67
Myriad Genetics	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

Sana Biotechnology has higher earnings, but lower revenue than Myriad Genetics. Sana Biotechnology is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sana Biotechnology	N/A	N/A	-$244.17M	-$0.76	N/A
Myriad Genetics	$824.50M	0.37	-$365.90M	-$1.19	N/A

Sana Biotechnology has a beta of 2.16, suggesting that its share price is 116% more volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

Sana Biotechnology has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Sana Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sana Biotechnology	N/A	-103.02%	-39.16%
Myriad Genetics	-13.96%	-16.09%	-8.10%

In the previous week, Sana Biotechnology had 5 more articles in the media than Myriad Genetics. MarketBeat recorded 6 mentions for Sana Biotechnology and 1 mentions for Myriad Genetics. Sana Biotechnology's average media sentiment score of 0.56 beat Myriad Genetics' score of 0.30 indicating that Sana Biotechnology is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sana Biotechnology	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Myriad Genetics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Sana Biotechnology beats Myriad Genetics on 10 of the 15 factors compared between the two stocks.

How does Myriad Genetics compare to Avalo Therapeutics?

Avalo Therapeutics (NASDAQ:AVTX) and Myriad Genetics (NASDAQ:MYGN) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, media sentiment, earnings and risk.

Avalo Therapeutics has higher earnings, but lower revenue than Myriad Genetics. Avalo Therapeutics is trading at a lower price-to-earnings ratio than Myriad Genetics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Avalo Therapeutics	$60K	17,724.72	-$78.26M	-$4.37	N/A
Myriad Genetics	$824.50M	0.37	-$365.90M	-$1.19	N/A

Avalo Therapeutics has a net margin of 0.00% compared to Myriad Genetics' net margin of -13.96%. Myriad Genetics' return on equity of -16.09% beat Avalo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Avalo Therapeutics	N/A	-58.03%	-48.22%
Myriad Genetics	-13.96%	-16.09%	-8.10%

Avalo Therapeutics has a beta of 0.8, suggesting that its share price is 20% less volatile than the broader market. Comparatively, Myriad Genetics has a beta of 1.69, suggesting that its share price is 69% more volatile than the broader market.

In the previous week, Myriad Genetics had 1 more articles in the media than Avalo Therapeutics. MarketBeat recorded 1 mentions for Myriad Genetics and 0 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 0.30 equaled Myriad Genetics'average media sentiment score.

Company	Overall Sentiment
Avalo Therapeutics	Neutral
Myriad Genetics	Neutral

Avalo Therapeutics currently has a consensus target price of $45.10, suggesting a potential upside of 127.43%. Myriad Genetics has a consensus target price of $4.90, suggesting a potential upside of 53.13%. Given Avalo Therapeutics' stronger consensus rating and higher probable upside, equities analysts clearly believe Avalo Therapeutics is more favorable than Myriad Genetics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Avalo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.86
Myriad Genetics	2 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.86

87.1% of Avalo Therapeutics shares are owned by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are owned by institutional investors. 4.5% of Avalo Therapeutics shares are owned by insiders. Comparatively, 1.9% of Myriad Genetics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

Myriad Genetics beats Avalo Therapeutics on 8 of the 15 factors compared between the two stocks.

Get Myriad Genetics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MYGN vs. The Competition

Export

Metric	Myriad Genetics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$306.08M	$4.01B	$7.37B	$12.83B
Dividend Yield	N/A	3.64%	2.53%	10.78%
P/E Ratio	-2.69	6.76	211.58	20.91
Price / Sales	0.37	1,341.06	625.25	96.27
Price / Cash	0.85	44.94	29.03	36.90
Price / Book	0.81	17.38	11.25	6.42
Net Income	-$365.90M	-$22.72M	$3.47B	$348.89M
7 Day Performance	5.61%	3.29%	2.09%	0.08%
1 Month Performance	-43.86%	8.23%	6.64%	3.88%
1 Year Performance	-46.84%	55.05%	25.02%	16.98%

Myriad Genetics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MYGN Myriad Genetics	2.7638 of 5 stars	$3.20 -0.6%	$4.90 +53.1%	-46.8%	$306.08M	$824.50M	N/A	2,700	Analyst Forecast
SVRA Savara	1.8096 of 5 stars	$5.37 -0.2%	$10.14 +88.9%	+76.9%	$1.11B	N/A	N/A	20
FBRX Forte Biosciences	1.4022 of 5 stars	$76.89 +0.1%	$71.67 -6.8%	+573.0%	$1.07B	N/A	N/A	5
WVE WAVE Life Sciences	2.7742 of 5 stars	$5.09 -5.9%	$22.53 +342.6%	-47.9%	$1.07B	$42.73M	N/A	240	Analyst Downgrade
SANA Sana Biotechnology	2.2036 of 5 stars	$3.68 +3.7%	$9.33 +153.6%	+9.2%	$1.06B	N/A	N/A	380

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MYGN) was last updated on 8/23/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Myriad Genetics (MYGN) Competitors

MYGN vs. SVRA, FBRX, WVE, SANA, and AVTX

How does Myriad Genetics compare to Savara?

Summary

How does Myriad Genetics compare to Forte Biosciences?

Summary

How does Myriad Genetics compare to WAVE Life Sciences?

Summary

How does Myriad Genetics compare to Sana Biotechnology?

Summary

How does Myriad Genetics compare to Avalo Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Myriad Genetics (MYGN) Competitors

MYGN vs. SVRA, FBRX, WVE, SANA, and AVTX

How does Myriad Genetics compare to Savara?

Is MYGN or SVRA more profitable?

Do analysts prefer MYGN or SVRA?

Which has more volatility & risk, MYGN or SVRA?

Does the media prefer MYGN or SVRA?

Do insiders & institutionals believe in MYGN or SVRA?

Which has higher earnings & valuation, MYGN or SVRA?

Summary

How does Myriad Genetics compare to Forte Biosciences?

Do analysts rate FBRX or MYGN?

Which has better valuation & earnings, FBRX or MYGN?

Is FBRX or MYGN more profitable?

Which has more risk and volatility, FBRX or MYGN?

Do insiders and institutionals believe in FBRX or MYGN?

Does the media refer more to FBRX or MYGN?

Summary

How does Myriad Genetics compare to WAVE Life Sciences?

Which has more risk and volatility, MYGN or WVE?

Do insiders and institutionals have more ownership in MYGN or WVE?

Is MYGN or WVE more profitable?

Does the media favor MYGN or WVE?

Do analysts rate MYGN or WVE?

Which has higher valuation & earnings, MYGN or WVE?

Summary

How does Myriad Genetics compare to Sana Biotechnology?

Do insiders & institutionals have more ownership in SANA or MYGN?

Do analysts prefer SANA or MYGN?

Which has stronger earnings & valuation, SANA or MYGN?

Which has more volatility & risk, SANA or MYGN?

Is SANA or MYGN more profitable?

Does the media refer more to SANA or MYGN?

Summary

How does Myriad Genetics compare to Avalo Therapeutics?

Which has better earnings and valuation, AVTX or MYGN?

Is AVTX or MYGN more profitable?

Which has more volatility and risk, AVTX or MYGN?

Does the media refer more to AVTX or MYGN?

Do analysts prefer AVTX or MYGN?

Do institutionals and insiders have more ownership in AVTX or MYGN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MYGN vs. The Competition

Myriad Genetics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools